Aktis Oncology (NASDAQ:AKTS) Shares Up 5.4% – What’s Next?

Aktis Oncology (NASDAQ:AKTS) shares were up 5.4% on Monday . The stock traded as high as $15.63 and last traded at $16.0040. Approximately 62,236 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 351,844 shares. The stock had previously closed at $15.19.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AKTS. TD Cowen began coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Leerink Partners started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price for the company. Finally, Bank of America began coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating and a $34.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Aktis Oncology currently has a consensus rating of “Buy” and a consensus target price of $32.00.

Aktis Oncology Price Performance

The company’s fifty day moving average price is $19.19.

Insider Buying and Selling

In related news, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of the stock in a transaction on Monday, January 12th. The stock was bought at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the acquisition, the insider directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This represents a 17.26% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ecor1 Capital, Llc bought 2,222,222 shares of the company’s stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $39,999,996.00. Following the transaction, the director directly owned 4,348,658 shares in the company, valued at approximately $78,275,844. This represents a 104.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 6,117,776 shares of company stock valued at $110,119,968 over the last ninety days.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.